within Pharmacolibrary.Drugs.ATC.J;

model J06BB19
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.0333333333333333e-07,
    adminDuration  = 600,
    adminMass      = 420 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0040999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.006900000000000001,
    k12             = 0.015,
    k21             = 0.015
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J06BB19</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Anthrax immunoglobulin is a human immune globulin preparation derived from the plasma of healthy donors immunized with anthrax vaccine. It contains polyclonal antibodies against Bacillus anthracis toxins and is used as an adjunctive treatment for inhalational anthrax in combination with appropriate antibacterial drugs. Anthrax immunoglobulin is FDA-approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated based on general properties of intravenous immunoglobulin (IVIg) products in healthy and infected adults, as no published population PK studies specific to anthrax immunoglobulin were found.</p><h4>References</h4><ol><li><p>Mytle, N, et al., &amp; Skiadopoulos, MH (2013). Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. <i>Antimicrobial agents and chemotherapy</i> 57(11) 5684–5692. DOI:<a href=\"https://doi.org/10.1128/AAC.00458-13\">10.1128/AAC.00458-13</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23979731/\">https://pubmed.ncbi.nlm.nih.gov/23979731</a></p></li><li><p>Oosterholt, SP, &amp; Della Pasqua, O (2021). Population pharmacokinetics of raxibacumab in healthy adult subjects. <i>British journal of clinical pharmacology</i> 87(12) 4718–4725. DOI:<a href=\"https://doi.org/10.1111/bcp.14894\">10.1111/bcp.14894</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33973655/\">https://pubmed.ncbi.nlm.nih.gov/33973655</a></p></li><li><p>Nagy, CF, et al., &amp; Guttendorf, R (2018). Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans. <i>Clinical pharmacology in drug development</i> 7(6) 652–660. DOI:<a href=\"https://doi.org/10.1002/cpdd.410\">10.1002/cpdd.410</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29125719/\">https://pubmed.ncbi.nlm.nih.gov/29125719</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J06BB19;
